Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis

Fundamental and Clinical Pharmacology

Volumn 26, Issue 5, 2012, Pages 589-598

  Saadatzadeh, Afrooz ^a   Atyabi, Fatemeh ^a   Fazeli, Mohammad Reza ^a,b   Dinarvand, Rassoul ^a   Jamalifar, Hossein ^a,b   Abdolghaffari, Amir Hossein ^b   Mahdaviani, Parvin ^b   Mahbod, Mirgholamreza ^c   Baeeri, Maryam ^a,b   Baghaei, Amir ^a,b   Mohammadirad, Azadeh ^a,b   Abdollahi, Mohammad ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NOOR EYE HOSPITAL   (Iran)

Author keywords

Colitis; Inflammatory bowel disease; Lyophilized probiotic extract; Nanoparticle

Indexed keywords

CHITOSAN; DEXAMETHASONE; INTERLEUKIN 1BETA; LYOPHILIZED PROBIOTIC EXTRACT; MYELOPEROXIDASE; NANOPARTICLE; POLYGLACTIN; PROBIOTIC AGENT; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; LIPID PEROXIDATION; MALE; NANOENCAPSULATION; NONHUMAN; PHYSICAL CHEMISTRY; PILOT STUDY; PRIORITY JOURNAL; RAT; THERAPY EFFECT;

ANIMALS; CHITOSAN; COLITIS; CYTOKINES; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FREEZE DRYING; INFLAMMATION MEDIATORS; LACTIC ACID; LIPID PEROXIDATION; MALE; NANOPARTICLES; PILOT PROJECTS; POLYGLYCOLIC ACID; PROBIOTICS; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID;

EID: 84865798683     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00966.x     Document Type: Article

References (53)

1. Rezaie A., Parker R.D., Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig. Dis. Sci. (2007) 52 2015-2021.
2. Zigra P.I., Maipa V.E., Alamanos Y.P. Probiotics and remission of ulcerative colitis: a systematic review. Neth. J. Med. (2007) 65 411-418.
3. Shanahan F. Probiotics in inflammatory bowel disease-therapeutic rationale and role. Adv. Drug Deliv. Rev. (2004) 56 809-818.
4. Kuhbacher T., Folsch U.R. Practical guidelines for the treatment of inflammatory bowel disease. World J. Gastroenterol. (2007) 13 1149-1155.
5. Rahimi R., Nikfar S., Rezaie A., Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig. Dis. Sci. (2007) 52 2920-2925.
6. Nikfar S., Rahimi R., Rahimi F., Derakhshani S., Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis. Colon Rectum (2008) 51 1775-1780.
7. Elahi B., Nikfar S., Derakhshani S., Vafaie M., Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig. Dis. Sci. (2008) 53 1278-1284.
8. Rahimi R., Nikfar S., Rezai A., Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch. Med. Sci. (2008) 4 185-190.
9. Rahimi R., Nikfar S., Rahimi F. et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig. Dis. Sci. (2008) 53 2524-2531.
10. Report of a joint FAO/WHO expert consultation on evaluation of Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. (2001) http://www.fao.org/ag/agns/micro_Probiotics_en.asp. ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf.
11. Hickson M., D'Souza A.L., Muthu N. et al. Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double-blind placebo controlled trial. B. M. J. (2007) 335 80.
12. Harish K., Varghese T. Probiotics in human-evidence based review. Calicut. Med. J. (2006) 4 e3.
13. Tien M.T., Girardin S.E., Regnault B. et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J. Immunol. (2006) 176 1228-1237.
14. + T cell-imediated skin inflammations. Eur. J. Immunol. (2004) 34 2520-2528.
15. Parassol N., Freitas M., Thoreux K., Dalmasso G., Bourdet-Sicard R., Rampal P. Lactobacillus casei DN-114001 inhibits the increase of paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res. Microbiol. (2005) 156 256-262.
16. Pishva E., Hssannia N., Fazeli M.R. et al. Antibacterial effect of authochlorous Lactobacillus strains isolated from traditional yogurt. P.J.N. (2009) 8 1132-1137.
17. Borruel N., Casellas F., Antolin M. et al. Effect of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am. J. Gastroenterol. (2003) 98 865-870.
18. Borruel N., Carol M., Casellas F. et al. Increased mucosal TNF-α production in Crohn's disease can be down regulated ex vivo by probiotic bacteria. Gut (2002) 5 659-664.
19. Llopis M., Antolin M., Guarner F., Salas A., Malagelada J.R. Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitrobenzene sulphonic acid. Gut (2005) 54 955-959.
20. Vinderola G., Matar C., Palacios J., Perdigon G. Mucosal immunomodulation by the non-bacterial fraction of milk fermented by Lactobacillus helveticus R 389. Int. J. Food Microbiol. (2007) 115 180-186.
21. Foo H.L., Loh T.C., Lai P.W., Lim Y.Z., Kufli C.N., Rusul G. Effect of adding Lactobacillus plantarum 1-UL4 metabolites in drinking water of rats. P.J.N. (2003) 2 283-288.
22. Piarroux R., Millon L., Bardonnet K., Vagner O., Koenig H. Are live saccharomyces yeasts harmful to patients? Lancet (1999) 353 1851-1852.
23. Kailasapathy K. Microencapsulation of probiotic bacteria technology and potential applications. Curr. Issues Intest. Microbiol. (2002) 3 39-48.
24. Esmaeili F., Ghahremani M.H., Esmaeili B., Khoshayand M.R., Atyabi F., Dinarvand R. PLGA Nan particles of different surface properties: preparation and evaluation of their body distribution. Int. J. Pharm. (2008) 349 249-255.
25. Lampercht A., Ubrich N., Yamamoto H. et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. (2001) 299 775-781.
26. Tabata Y., Inoue Y., Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine (1996) 14 1677-1685.
27. Pertuit D., Moulari B., Betz T. et al. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J. Control. Release (2007) 123 211-218.
28. Abdolghafari A.H., Baghai A., Moayer F. et al. On the benefit of Teucrium in murine colitis through improvement or toxic inflammatory mediators. Hum. Exp. Toxicol. (2010) 29 287-295.
29. Esmaily H., Hosseini-Tabatabaei A., Rahimian R. et al. On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. Cent. Eur. J. Biol. (2009) 4 204-213.
30. Abdollahi M., Dehpour A.R., Baharnouri G. Alteration by rubidium of rat submandibular secretion of protein and N-acetyl-D-glucosaminidase. Toxic. Subst. Mech. (1998) 17 121-131.doi: 10.1080/107691898229369.
31. Ebrahimi F., Esmaily H., Baeeri M., Mommadirad A., Fallah S., Abdollahi M. Molecular evidences on the benefit of N-acetylcysteine in experimental colitis. Cent. Eur. J. Biol. (2008) 3 132-135.
32. Ghzanfari G., Minaie B., Yasa N. et al. Biochemical and histopathological evidences for beneficial effects of satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol. Mech. Methods (2006) 16 365-372.
33. Astaneie F., Afshari M., Mojtahedi A. et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch. Med. Res. (2005) 36 376-381.
34. Lowry O.H., Rosebrough N.J., Farr A.L., Randall Rj. Protein measurement with the folin phenol reagent. J. Biol. Chem. (1951) 19 265-275.
35. Hegazy S.K., El-Bedewy M.M. Effect of probiotics on pro-inflammatory cytokines and Nf-κB activation in Ulcerative Colitis. World J. Gastroenterol. (2010) 16 4145-4151.
36. Zhang D.K., Cheng L.N., Huang X.L., Shi W., Xiang J.Y., Gan H.T. Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice though inhibition of nuclear factor-kappa B activation. Int. J. Colorectal Dis. (2009) 24 5-12.
37. Shen C., de Hertogh G., Bullens D.M. et al. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm. Bowel Dis. (2007) 13 308-316.
38. Rahimi R., Nikfar S., Abdollahi M. Do ant-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed. pharmacother. (2007) 61 75-80.
39. Rahimi R., Nikfar S., Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-α in the management of active ulcerative colitis when administered in combination with corticostroides. Med. Sci. Monit. (2007) 13 PI13-PI18.
40. Hosseini-Tabatabaei A., Esmaily H., Rahimian R. et al. Benefit of nicorandil using an immunologic murine model of experimental colitis. Cent. Eur. J. Biol. (2009) 4 74-85.
41. Bai A.P., Ouyang Q., Xiao X.R., Li S.F. Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. Int. J. Clin. Pract. (2006) 60 284-288.
42. Shi X.Z., Lindholm P.F., Sarna S.K. NF-kappa B activation by oxidative stress and inflammation suppresses contractility in colonic circular smooth muscle cells. Gastroenterology (2003) 124 1369-1380.
43. Esmaily H., Vaziri-Bami A., Miroliaee A.E., Baeeri M., Abdollahi M. The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam. Clin. Pharmacol. (2010). doi: 10.1111/j.1472-8206.2010.00893.x. [Epub ahead of print] PubMed PMID: 21077947.
44. Miroliaee A.E., Esmaily H., Vaziri-Bami A., Baeeri M., Shahverdi A.R., Abdollahi M. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol. Mech. Methods (2011) 21 200-208.
45. Federico A., Tuccillo C., Grossi E. et al. The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. Eur. Rev. Med. Pharmacol. Sci. (2009) 13 285-293.
46. Lee J.H., Lee B., Lee H.S. et al. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4 linked NF-kappaB activation in experimental colitis. Int. J. Colorectal Dis. (2009) 24 231-237.
47. Neish As., Gewirtz A.T., Zeng H. et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-α ubiquitination. Science (2000) 289 1560-1563.
48. Amini-Shirazi N., Hoseini A., Ranjbar A. et al. Inhibition of tumor necrosis factor and nitrosative/oxidative stresses by Ziziphora clinopoides (Kahlioti); a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice. Toxicol. Mech. Methods (2009) 19 183-189.
49. Rahimi R., Mozaffari S., Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig. Dis. Sci. (2009) 54 471-480.
50. Toklu H.Z., Tunali Akbay T., Velioglu-Ogunc A. et al. Silymarin, the antioxidant component of silybum marianum, prevents sepsis-induced acute lung and brain injury. J. Surg. Res. (2008) 145 214-222.
51. Jurjus A.R., Khoury N.N., Reimund J.M. Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods (2004) 50 81-92.
52. Atyabi F., Majzoob S., Dorkoosh F., Sayyah M., Ponchel G. The impact of trimethyl chitosan on invitro mucoadhesive properties of pectinate beads along different sections of gastrointestinal tract. Drug Dev. Ind. Pharm. (2007) 33 291-300.
53. Atyabi F., Majzoob S., Iman M., Salehi M., Dorkoosh F. Invitro evaluation and modification of pectinate gel beads containing trimethyl chitosan as a multi-particulate system for delivery of water-soluble macro molecules to colon. Carbohydr. Polym. (2005) 61 39-51.